CN1128619C - 含有羟基吡啶酮的粉末制剂用于治疗腿部溃疡和压迫溃疡的用途 - Google Patents

含有羟基吡啶酮的粉末制剂用于治疗腿部溃疡和压迫溃疡的用途 Download PDF

Info

Publication number
CN1128619C
CN1128619C CN99802327A CN99802327A CN1128619C CN 1128619 C CN1128619 C CN 1128619C CN 99802327 A CN99802327 A CN 99802327A CN 99802327 A CN99802327 A CN 99802327A CN 1128619 C CN1128619 C CN 1128619C
Authority
CN
China
Prior art keywords
group
formula
pyridone
hydroxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN99802327A
Other languages
English (en)
Chinese (zh)
Other versions
CN1288380A (zh
Inventor
M·波恩
K·T·克里默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Publication of CN1288380A publication Critical patent/CN1288380A/zh
Application granted granted Critical
Publication of CN1128619C publication Critical patent/CN1128619C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CN99802327A 1998-01-24 1999-01-11 含有羟基吡啶酮的粉末制剂用于治疗腿部溃疡和压迫溃疡的用途 Expired - Lifetime CN1128619C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19802708.7 1998-01-24
DE19802708A DE19802708A1 (de) 1998-01-24 1998-01-24 Verwendung von hydroxypyridon-haltigen Puderzubereitungen zur Behandlung von Unterschenkel- und Druckgeschwüren

Publications (2)

Publication Number Publication Date
CN1288380A CN1288380A (zh) 2001-03-21
CN1128619C true CN1128619C (zh) 2003-11-26

Family

ID=7855595

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99802327A Expired - Lifetime CN1128619C (zh) 1998-01-24 1999-01-11 含有羟基吡啶酮的粉末制剂用于治疗腿部溃疡和压迫溃疡的用途

Country Status (27)

Country Link
US (1) US6534528B1 (enExample)
EP (1) EP1049468B1 (enExample)
JP (1) JP5127091B2 (enExample)
KR (1) KR100597332B1 (enExample)
CN (1) CN1128619C (enExample)
AR (1) AR016445A1 (enExample)
AT (1) ATE360418T1 (enExample)
AU (1) AU752406B2 (enExample)
BR (1) BR9907734A (enExample)
CA (1) CA2319359C (enExample)
CY (1) CY1106684T1 (enExample)
DE (2) DE19802708A1 (enExample)
DK (1) DK1049468T3 (enExample)
ES (1) ES2285829T3 (enExample)
HR (1) HRP20000496A2 (enExample)
HU (1) HU228824B1 (enExample)
IL (1) IL137453A (enExample)
ME (1) MEP55908A (enExample)
NZ (1) NZ505898A (enExample)
PL (1) PL192550B1 (enExample)
PT (1) PT1049468E (enExample)
RS (1) RS50903B (enExample)
RU (1) RU2212239C2 (enExample)
SI (1) SI1049468T1 (enExample)
SK (1) SK285350B6 (enExample)
TR (1) TR200002118T2 (enExample)
WO (1) WO1999037300A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001122804A (ja) * 1999-10-28 2001-05-08 Sato Pharmaceutical Co Ltd リン酸コーンスターチ配合外用医薬組成物
EP1354586A1 (en) * 2002-04-20 2003-10-22 Aventis Pharma Deutschland GmbH The use of hydroxpyridone-derivatives in wound healing
US20060257439A1 (en) * 2005-03-29 2006-11-16 Sabnis Ram W Cleansing compositions with color changing indicator
RU2326665C1 (ru) * 2007-04-03 2008-06-20 Марвел ЛайфСайнсез Лимитед, Великобритания Средство, обладающее противогипоксическим, противоинсультным, улучшающим память действием
ES2525387T3 (es) * 2010-07-27 2014-12-23 Clariant Finance (Bvi) Limited Composiciones que contienen peróxido de hidrógeno o sustancias que ponen en libertad peróxido de hidrógeno
BR112013001953A2 (pt) * 2010-07-27 2018-05-15 Clariant Finance Bvi Ltd uso de hidroxipiridonas ou sais dos mesmos para a estabilização de peróxido de hidrogênio ou substâncias doadoras de peróxido de hidrogênio
RS61907B1 (sr) 2015-04-06 2021-06-30 Subdomain Llc Polipeptidi koji sadrže de novo vezujući domen i njihova primena

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020560A1 (de) * 1995-12-04 1997-06-12 Hoechst Aktiengesellschaft Verwendung von 1-hydroxy-2-pyridonen zur behandlung von schwer therapierbaren schleimhauterkrankungen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2540218A (en) 1947-08-25 1951-02-06 Squibb & Sons Inc 2-hydroxy-pyridine-n-oxide and process for preparing same
AR242187A1 (es) * 1986-04-18 1993-03-31 Hoechst Ag Procedimiento para la preparacion de 1-hidroxi-2-piridonas, obtencion de medicamentos que las contienen, e intermediarios utiles en dicho procedimiento.
JPS63264504A (ja) * 1987-04-17 1988-11-01 Shinto Paint Co Ltd 工業用防カビ組成物
US4956184A (en) * 1988-05-06 1990-09-11 Alcide Corporation Topical treatment of genital herpes lesions
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
DE4333893A1 (de) 1993-10-05 1995-04-06 Hoechst Ag Kosmetische Zubereitungen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020560A1 (de) * 1995-12-04 1997-06-12 Hoechst Aktiengesellschaft Verwendung von 1-hydroxy-2-pyridonen zur behandlung von schwer therapierbaren schleimhauterkrankungen

Also Published As

Publication number Publication date
DK1049468T3 (da) 2007-07-30
HUP0200851A1 (hu) 2002-07-29
HRP20000496A2 (en) 2000-12-31
DE19802708A1 (de) 1999-07-29
TR200002118T2 (tr) 2000-12-21
YU43700A (sh) 2003-08-29
PL192550B1 (pl) 2006-11-30
ME00390B (me) 2011-05-10
WO1999037300A1 (de) 1999-07-29
AU752406B2 (en) 2002-09-19
CA2319359A1 (en) 1999-07-29
AR016445A1 (es) 2001-07-04
SK285350B6 (sk) 2006-11-03
JP2002501020A (ja) 2002-01-15
US6534528B1 (en) 2003-03-18
EP1049468B1 (de) 2007-04-25
AU2278799A (en) 1999-08-09
ATE360418T1 (de) 2007-05-15
IL137453A (en) 2005-11-20
EP1049468A1 (de) 2000-11-08
HU228824B1 (en) 2013-05-28
NZ505898A (en) 2002-06-28
PL342055A1 (en) 2001-05-21
BR9907734A (pt) 2000-10-17
MEP55908A (en) 2011-05-10
SI1049468T1 (sl) 2007-08-31
PT1049468E (pt) 2007-05-31
CA2319359C (en) 2008-03-18
CY1106684T1 (el) 2012-05-23
KR20010034325A (ko) 2001-04-25
IL137453A0 (en) 2001-07-24
ES2285829T3 (es) 2007-11-16
DE59914312D1 (de) 2007-06-06
SK10892000A3 (sk) 2000-12-11
HUP0200851A3 (en) 2003-05-28
CN1288380A (zh) 2001-03-21
RS50903B (sr) 2010-08-31
KR100597332B1 (ko) 2006-07-10
JP5127091B2 (ja) 2013-01-23
RU2212239C2 (ru) 2003-09-20
HK1034447A1 (en) 2001-10-26

Similar Documents

Publication Publication Date Title
JP4818516B2 (ja) 化合物の抗菌剤としての新規な使用
RU2241489C2 (ru) Композиции матриксных протеинов для залечивания ран
Vickers et al. Pharmacokinetics of EMLA cream 5% application to oral mucosa
CN1128619C (zh) 含有羟基吡啶酮的粉末制剂用于治疗腿部溃疡和压迫溃疡的用途
JP2004501966A (ja) 全身の健康の増進
US20130102562A1 (en) Inhibition of cathepsin k activity and the treatment and prevention of disease
CN1635880A (zh) 双胍衍生物在制备具有瘢痕形成作用的医药产品中的应用
BR0316261A (pt) Composto, composição farmacêutica que compreende o mesmo, método para tratar uma enfermidade caracterizada por renovação, ativação, ou renovação e ativação de leucócitos patogênicos e método de antagonização de um receptor de quimioquinas c-c 1 em um paciente
CN1343122A (zh) 关节性疾病治疗剂
EP3145533B1 (en) Compositions for promoting the healing of wounds
CN1889965A (zh) 使用生物相容聚合物,制备一种化合物或制造一种医用设备
JP5025045B2 (ja) 多硫酸化多糖類によるtimp産生の亢進
JPH04234815A (ja) コラゲナーゼの活性化及びミエロパーオキシダーゼの活性を阻害するためのテニダップ
CN102988962A (zh) 一种用于预防或治疗皮肤瘙痒症的复合物
CN1455679A (zh) Melagatran用于制备治疗局部缺血症的药物的用途
HK1034447B (en) Utilization of powder preparations containing hydroxypyridones for treating leg ulcers and decubitus ulcers
CN1278692C (zh) 地榆多糖制剂及其制备方法与应用
Rawat et al. An overview of miracle enzyme-serratiopeptidase
CZ295316B6 (cs) Léčivo k léčbě bércových vředů a proleženin
CA2561032A1 (en) Inhibition of cathepsin k activity and the treatment and prevention of disease
AU2006222712A1 (en) Inhibition of Cathepsin K Activity and the treatment and prevention of disease
JP2015034150A (ja) 難治性創傷の治癒促進剤
WO2008031440A2 (en) Isoniazid mediated healing of wounds and ulcers
TW200824702A (en) Pharmaceutical composition for treating aristolochic acid nephropathy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: SANOFI- AVENTIS GERMAN CO., LTD.

Free format text: FORMER NAME OR ADDRESS: AVENTIS PHARMACY (GERMANY)INTERNATIONAL CO., LTD.

CP01 Change in the name or title of a patent holder

Address after: Frankfurt, Germany

Patentee after: Hoechst Marion Roussel de GmbH

Address before: Frankfurt, Germany

Patentee before: Awentis Medicines Deutschland GmbH

CX01 Expiry of patent term

Granted publication date: 20031126

CX01 Expiry of patent term